Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025

5. Eli Lilly and Company (NYSE:LLY)

Millennium Management’s Stake Value: $877.27 Million

Number of Hedge Fund Holders: 106

Eli Lilly and Company (NYSE:LLY) is a healthcare company that discovers, develops, and markets human pharmaceuticals worldwide. It’s been a strong winner over the past few years due to the strong demand for diabetes and weight loss drugs. The stock was up by about 26% in 2024, emerging as one of billionaire Israel Englander’s top stock picks.

Eli Lilly and Company (NYSE:LLY) has experienced a remarkable surge, fueled by high demand for their medications, Mounjaro and Zepbound. Zepbound is approved to help obese or overweight adults with at least one weight-related condition lose weight. Mounjaro has also been approved to help adult patients with type 2 diabetes improve their blood glucose levels.

Wall Street is incredibly excited about the company’s long-term prospects as it is working on a GLP-1 weight loss pill. Eli Lilly and Company (NYSE:LLY) anticipates having information to share on a late-stage trial for orforglipron, an oral GLP-1 drug that has shown promise by April 2025. The once-daily pill has already posted solid results in helping overweight or obese people lose up to 14.7% of their body weight over a 36-week period.

In addition to weight loss pills, Eli Lilly and Company (NYSE:LLY) also boasts of a robust and diverse pipeline of drugs. It sells a number of lucrative drugs that are used to treat conditions like plaque psoriasis and cancer. The FDA also approved the company’s eczema and Alzheimer’s disease treatments this year.